Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

TAVIPILOT Soft is said to be a ‘world-first’ provision for real-time surgical guidance during TAVI and TAVR procedures.

CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in ...

The global heart valve frame market is poised for significant growth over the coming years, driven by factors such as increasing prevalence of cardiovascular ...

Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...

Abbott introduces Navitor Vision in India, the next generation of heart valve technology designed to treat aortic stenosis: Our Bureau, Mumbai Thursday, January 30, 2025, 15:15 Hr ...

At baseline, the mechanical valve group tended to be younger (55.7 vs 65.2) and had less aortic stenois (82.4% vs 89.5%), but ...

LOS ANGELES -- Cardiac surgeons were urged to readjust their attitudes toward the tricuspid valve if they want to keep some ...

Stifel analysts upgraded Edwards Lifesciences (NYSE:EW) stock from Hold to Buy, citing potential growth acceleration in the Transcatheter Aortic Valve Replacement (TAVR) market. The firm also ...

The Navitor Vision, Abbott's latest TAVI system, is designed to improve accuracy during implantation and enhance visibility ...

We recently compiled a list of the 12 Best Fundamental Stocks to Buy Now. In this article, we are going to take a look at ...